ZYXI Stock Overview
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zynex, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.38 |
52 Week High | US$17.25 |
52 Week Low | US$6.56 |
Beta | 0.59 |
1 Month Change | -29.69% |
3 Month Change | -25.61% |
1 Year Change | 34.58% |
3 Year Change | -48.38% |
5 Year Change | 189.02% |
Change since IPO | 339.06% |
Recent News & Updates
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Recent updates
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Short Squeeze Candidate With Low PEG Ratio: Zynex
Oct 05Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
Sep 21These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely
Aug 02Zynex Cures The Pain Of Its Shareholders: Q2 Results
Aug 01Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain
Jul 25Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?
Jul 12Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance
Jul 11Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?
Apr 13Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Mar 23Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA
Feb 17Zynex: Turnaround Nears Inevitable End - Largest Payor Cuts TENS Reimbursement, May Eliminate Earnings
Dec 10Zynex: A Fact Finding Mission
Sep 03Zynex Took A Back Seat Due To Covid-19
Aug 22Zynex, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 04What Does Zynex, Inc.'s (NASDAQ:ZYXI) Share Price Indicate?
Mar 09Have Insiders Been Selling Zynex, Inc. (NASDAQ:ZYXI) Shares?
Feb 16Is There More To The Story Than Zynex's (NASDAQ:ZYXI) Earnings Growth?
Feb 02Is Zynex, Inc. (NASDAQ:ZYXI) Popular Amongst Insiders?
Jan 20Zynex announces filing of patent for sepsis monitor
Jan 14Zynex: Operating Inefficiencies And Gross-To-Net Challenges Place Ceiling On Scalability
Jan 12Zynex announces second utility patent for its blood volume monitor
Jan 06Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Jan 05Does Zynex (NASDAQ:ZYXI) Deserve A Spot On Your Watchlist?
Dec 23Is Weakness In Zynex, Inc. (NASDAQ:ZYXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Dec 08Should You Investigate Zynex, Inc. (NASDAQ:ZYXI) At US$13.62?
Nov 24Shareholder Returns
ZYXI | US Medical Equipment | US Market | |
---|---|---|---|
7D | -1.8% | -1.2% | 1.0% |
1Y | 34.6% | 2.7% | -0.2% |
Return vs Industry: ZYXI exceeded the US Medical Equipment industry which returned 2.7% over the past year.
Return vs Market: ZYXI exceeded the US Market which returned -0.2% over the past year.
Price Volatility
ZYXI volatility | |
---|---|
ZYXI Average Weekly Movement | 14.1% |
Medical Equipment Industry Average Movement | 7.6% |
Market Average Movement | 6.5% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZYXI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ZYXI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 900 | Thomas Sandgaard | https://www.zynex.com |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products.
Zynex, Inc. Fundamentals Summary
ZYXI fundamental statistics | |
---|---|
Market Cap | US$337.84m |
Earnings (TTM) | US$17.24m |
Revenue (TTM) | US$169.25m |
19.8x
P/E Ratio2.0x
P/S RatioIs ZYXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZYXI income statement (TTM) | |
---|---|
Revenue | US$169.25m |
Cost of Revenue | US$33.99m |
Gross Profit | US$135.26m |
Other Expenses | US$118.02m |
Earnings | US$17.24m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.47 |
Gross Margin | 79.92% |
Net Profit Margin | 10.19% |
Debt/Equity Ratio | 14.4% |
How did ZYXI perform over the long term?
See historical performance and comparison